Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL599 (Acticam, Anjeso, Contacera, Coxicam, Emdocam, Flexicam, Inflacam, Loxicom, Melfax, Melosus, Melovem, Meloxicam, Meloxidolor, Meloxidyl, Meloxivet, Meloxoral, Metacam, Mobic, Movatec, N-1539, N1539, Qmiiz odt, Recocam, Revitacam, Rheumocam, UH-AC 62XX, UH-AC-62 XX, UHAC-62XX, Vivlodex) |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
COX-1 /Cyclooxygenase-1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL221] [GtoPdb: 1375] [UniProtKB: P23219] | ||||||||
ChEMBL | Inhibition of COX-1 (unknown origin) | B | 4.07 | pIC50 | 85800 | nM | IC50 | Eur J Med Chem (2021) 225: 113804-113804 [PMID:34479036] |
ChEMBL | Concentration of drug that causes a 50% decrease in the maximal inhibition of Prostaglandin G/H synthase 1 activity as measured by PGE-2 production (''++'' indicates 80-90% inhibition) | B | 4.44 | pIC50 | 36600 | nM | IC50 | J Med Chem (1997) 40: 980-989 [PMID:9083488] |
GtoPdb | - | - | 4.44 | pIC50 | 36600 | nM | IC50 | J Med Chem (1997) 40: 980-9 [PMID:9083488] |
ChEMBL | Inhibition of human recombinant COX1 assessed as reduction in PGF2alpha formation using arachidonic acid as substrate preincubated for 10 mins measured after substrate addition by microplate reader based enzyme immunoassay | B | 4.51 | pIC50 | 31200 | nM | IC50 | Bioorg Med Chem (2020) 28: 115526-115526 [PMID:32354672] |
ChEMBL | Concentration that caused a 50% decrease in the maximal inhibition of Prostaglandin G/H synthase 1 activity as measured by PGE-2 production. | B | 5.66 | pIC50 | 2200 | nM | IC50 | Bioorg Med Chem Lett (1998) 8: 1181-1186 [PMID:9871731] |
ChEMBL | In vitro for its inhibitory activity against human whole blood Prostaglandin G/H synthase 1 | B | 5.85 | pIC50 | 1400 | nM | IC50 | Bioorg Med Chem Lett (1999) 9: 1773-1778 [PMID:10406640] |
ChEMBL | DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) | B | 5.88 | pIC50 | 1319 | nM | IC50 | DrugMatrix in vitro pharmacology data |
ChEMBL | Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate and measured by fluorometric assay | B | 7.44 | pIC50 | 36.6 | nM | IC50 | Eur J Med Chem (2022) 241: 114597-114597 [PMID:35931005] |
Cyclooxygenase-1 in Sheep (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2949] [UniProtKB: P05979] | ||||||||
ChEMBL | Inhibition of ovine COX1 after 5 mins by enzyme immuno assay | B | 4.71 | pIC50 | 19400 | nM | IC50 | Medchemcomm (2015) 6: 283-299 |
ChEMBL | Inhibition of sheep seminal vesicle COX-1 assessed as reduction in oxygen consumption using arachidonic acid as substrate incubated for 12 mins followed by substrate addition measured for 2 mins | B | 6 | pIC50 | 1000 | nM | IC50 | Bioorg Med Chem (2017) 25: 316-326 [PMID:27842798] |
COX-2 /Cyclooxygenase-2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL230] [GtoPdb: 1376] [UniProtKB: P35354] | ||||||||
ChEMBL | Inhibition of COX-2 (unknown origin) | B | 4.15 | pIC50 | 71500 | nM | IC50 | Eur J Med Chem (2021) 225: 113804-113804 [PMID:34479036] |
ChEMBL | Inhibition of COX2 (unknown origin) assessed as suppression of PGG2 conversion to PGH2 incubated fro 2 mins by TMPD based colorimetric assay | B | 4.24 | pIC50 | 57300 | nM | IC50 | Bioorg Med Chem (2019) 27: 3918-3928 [PMID:31345747] |
ChEMBL | Inhibition of human COX-2 using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition and measured after 2 mins by colorimetric assay | B | 5.62 | pIC50 | 2400 | nM | IC50 | RSC Med Chem (2022) 13: 471-496 [PMID:35685617] |
ChEMBL | DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) | B | 6.03 | pIC50 | 938 | nM | IC50 | DrugMatrix in vitro pharmacology data |
ChEMBL | In vitro inhibitory activity against human whole blood Prostaglandin G/H synthase 2 | B | 6.15 | pIC50 | 700 | nM | IC50 | Bioorg Med Chem Lett (1999) 9: 1773-1778 [PMID:10406640] |
ChEMBL | Concentration of drug that causes a 50% decrease in the maximal inhibition of Prostaglandin G/H synthase 2 activity as measured by PGE-2 production | B | 6.31 | pIC50 | 490 | nM | IC50 | J Med Chem (1997) 40: 980-989 [PMID:9083488] |
GtoPdb | - | - | 6.31 | pIC50 | 490 | nM | IC50 | J Med Chem (1997) 40: 980-9 [PMID:9083488] |
ChEMBL | Inhibition of human recombinant COX2 assessed as reduction in PGH2 formation using arachidonic acid as substrate preincubated for 10 mins measured after substrate addition by microplate reader based enzyme immunoassay | B | 6.48 | pIC50 | 330 | nM | IC50 | Bioorg Med Chem (2020) 28: 115526-115526 [PMID:32354672] |
ChEMBL | Concentration that caused a 50% decrease in the maximal inhibition of Prostaglandin G/H synthase 2 activity as measured by PGE-2 production. | B | 6.8 | pIC50 | 160 | nM | IC50 | Bioorg Med Chem Lett (1998) 8: 1181-1186 [PMID:9871731] |
ChEMBL | Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate and measured by fluorometric assay | B | 9.31 | pIC50 | 0.49 | nM | IC50 | Eur J Med Chem (2022) 241: 114597-114597 [PMID:35931005] |
Cyclooxygenase-2 in Sheep (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4102] [UniProtKB: P79208] | ||||||||
ChEMBL | Inhibition of ovine COX2 after 5 mins by enzyme immuno assay | B | 5.86 | pIC50 | 1370 | nM | IC50 | Medchemcomm (2015) 6: 283-299 |
COX-2 /Cyclooxygenase-2 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4321] [GtoPdb: 1376] [UniProtKB: Q05769] | ||||||||
ChEMBL | Inhibition of mouse COX-2 expressed in baculovirus infected Sf21 insect cells assessed as reduction in oxygen consumption using arachidonic acid as substrate incubated for 12 mins followed by substrate addition measured for 2 mins | B | 6.82 | pIC50 | 151.36 | nM | IC50 | Bioorg Med Chem (2017) 25: 316-326 [PMID:27842798] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]